AlphAIalphai — Financial news for AI agents
StockNASDAQ · US · USDHealthcare · Medical Distribution

$FOCL

EDAP TMS SA

alphai earnings readSecond Quarter 2026 · AUG 13FocalTherics™ Reports Second Quarter 2026 Financial Results 39% Revenue Increase and 47% Growth in U.S. ProceduresVerdict: mixed

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

Price · $FOCLvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $FOCL in the last 7 days.

Insider · 30dAll trades →
Buys
$551K
8 txs
Sells
—
0 txs
WILLSEY LANCE1× · $238K
10b5-1 share of filings0%
See all $FOCL insider activity →
Top stories · $FOCLMore →
AUG 18·yahoo.comMed

FocalTherics (FOCL) Q2 2026 Earnings Call Transcript

FocalTherics (FOCL) reported Q2 2026 earnings with $13.2M in HIFU revenue, up 39% YoY. They sold 13 Focal One systems, a 44% increase. The company expanded its footprint in the U.S. and internationally, including sales to Cleveland Clinic and Kaiser Permanente. They submitted a 510(k) application for FocalConnect and expect CMS reimbursement increases. The company is also expanding into new indications like BPH and endometriosis, targeting a $10B revenue opportunity.

FOCL sentiment & insider activity

Recent FOCL coverage spans insider activity, earnings and corporate actions.

In the last 30 days, FOCL insiders filed 8 SEC Form 4 transactions — 8 purchases ($551K) and no sales. The most active reporter was WILLSEY LANCE with 1 filing.

What's driving FOCL

  • Q2 growth in HIFU revenue and capital system placements, plus CMS proposed 12% facility payment increase for 2027, supports a bullish near-term demand and utilization outlook.

    yahoo.com · Aug 18, 2026

  • A director open-market purchase is a modest insider signal, but it is not a fundamental catalyst by itself.

    SEC EDGAR · Aug 17, 2026

  • This is a disclosed insider open-market purchase by a director, which can be read as mild positive sentiment but is not a fundamental catalyst by itself.

    SEC EDGAR · Aug 17, 2026

  • This is a disclosed insider open-market purchase, which can be read as mild positive sentiment but is not a fundamental catalyst by itself.

    SEC EDGAR · Aug 17, 2026

  • This is a small insider open-market purchase with limited signal strength, but it can modestly support near-term sentiment.

    SEC EDGAR · Aug 17, 2026

alphai scores every news story that mentions FOCL with an AI model for sentiment and relevance, and aggregates insider trades from EDAP TMS SA's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $FOCL

Score
AUG 18$FOCLMedAI 8/10yahoo.com

FocalTherics (FOCL) Q2 2026 Earnings Call Transcript

FocalTherics (FOCL) reported Q2 2026 earnings with $13.2M in HIFU revenue, up 39% YoY. They sold 13 Focal One systems, a 44% increase. The company expanded its footprint in the U.S. and internationally, including sales to Cleveland Clinic and Kaiser Permanente. They submitted a 510(k) application for FocalConnect and expect CMS reimbursement increases. The company is also expanding into new indications like BPH and endometriosis, targeting a $10B revenue opportunity.

7 min read
AUG 14$FOCLMedSEC EDGAR 8-K

EDAP TMS SA (FOCL): Entry into a Material Definitive Agreement

EDAP TMS SA (FOCL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Underwriting Agreement On August 11, 2026, EDAP TMS S.A. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC and Mizuho Securities USA LLC, as representatives (the

6 min read

Related tickers

More in Medical Distribution